Ketasma
Indicated to address allergic airway reactivity to manage asthma symptoms and alleviate persistent bronchial spasms.
- Categories
- Respiratory Health · Allergy Relief
- Active ingredient
- Ketotifen
- Route
- Oral use
- Form
- Tablet
- Strengths
- 1mg
Prescription and consultation requirements for Ketasma vary by destination and are determined by the fulfilment partner.
Ketasma details
- Conditions
- Allergic Conjunctivitis · Asthma Prophylaxis
- Alternative names
- ketotifen
- Therapeutic class
- H1 Receptor Antagonist, Mast Cell Stabiliser
- Pharmacological class
- Antihistamine
- Known off-label uses
- atopic dermatitis
- Contraindications
- uncontrolled epilepsy; hypersensitivity to ketotifen
- Minor side effects
- drowsiness; dry mouth; dizziness
- Moderate side effects
- increased appetite; weight gain; excitement in children
- Serious side effects
- severe convulsions, requires immediate medical attention
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Sun Pharmaceutical Industries Ltd
- Onset Time
- 2–4 weeks
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Oral Hypoglycaemics; Alcohol; CNS Depressants
- Age restrictions
- Approved for children over three years and adults.
- Pregnancy and breastfeeding
- TGA Category C: Limited clinical records. Breastfeeding: Avoid.
Patient summary
indicated to address allergic airway reactivity to manage asthma symptoms and alleviate persistent bronchial spasms.
Mechanism of action
Combines non-competitive histamine H1 blockade with powerful stabilisation of mast cells to stop cytokine discharge.